Best of heart failure

32 relatively stable (INTERMACS 3 – 7) (Table 1 ) when planning for revasculari- zation. Moreover, a deep understanding of temporary AMCS platforms is critical since they may be indicated in these cases. Devices that are used to provide hemodynamic support during revascularization include the intra-aortic balloon pump (IABP), trans-valvular axial flow pumps, and veno-arterial ex- tracorporeal membrane oxygenator (VA-ECMO). Although IABP augments coronary perfusion, overall reduction in myocar- dial ischemia is limited by the fact that this device provides little or no reduction in native LV work and thus myocardial oxygen demand [ 22 ]. IABP works by diastolic augmentation and volume displacement mainly driven by the native heart ’ s pulsatility. In failing hearts, this effect is particularly modest because native pulsation is needed to achieve effective counterpulsation. For this and other reasons in patients with LV dysfunction undergoing IABP-assisted Fig. 3. Time-to-event and landmark analyses for death from any cause through 1 year of the CULPRIT-SHOCK trial. Panel a shows Kaplan – Meier estimates of the rate of death from any cause through 1 year. Panel b shows the rate of death from any cause through 30 days, as well as the rate between 30 days and 1 year. Curr Treat Options Cardio Med (2019) 21: 4 Page 7 of 12 4